Neurogene NGN-401 Rett Data: Efficacy and Safety Readout

Neurogene held a conference call June 29 to discuss updated Phase 1/2 data for NGN-401, a gene therapy for Rett syndrome. CEO Rachel McMinn and Chief Medical Officer Julie Jordan presented. Dr. Bernhard Suter, medical director of the Bluebird Circle Rett Center at Texas Children's Hospital, joined as a key opinion leader.

NGN-401 delivers a functional copy of the MECP2 gene. The therapy is given as a single intravenous dose. The Phase 1/2 trial is evaluating safety and efficacy in children with Rett syndrome.

The call included analysts from TD Cowen, LifeSci Capital, Guggenheim, Leerink Partners, Stifel, and H.C. Wainwright. The company did not disclose specific efficacy or safety numbers during the prepared remarks. Investors will review the full data set for signs of clinical benefit.